Literature DB >> 35348948

Pharmaceutical perspective of neuropathic pain management for primary care providers.

Sandhya Jinesh1, Justin Kullgren2, Gollapudi S Shankar3, Rajan Radhakrishnan4.   

Abstract

Neuropathic pain (NP) is a chronic condition that affects ~ 1% of the general population globally. Several conditions such as chronic diabetes, herpes zoster (HZ), cancer, HIV, stroke, multiple sclerosis, physical compression or damage of nerves and certain surgical procedures can lead to neuropathy and related pain. The condition is difficult to treat with traditional analgesic drugs. Typically, non-traditional analgesics are used in treating pain in this condition such as antidepressants and antiepileptic drugs. Opioids are useful in some patients, but the risk of addiction and the risk of both short-term and long-term adverse effects make it a low priority drug class in the treatment of NP. In the current review we discuss the pharmacology and pharmaceutical care aspects of various classes of drugs used in the treatment of NP, counselling points for these drug classes, and future prospects in the treatment of NP.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Neuropathic pain; Pharmaceutical; Pharmacotherapy; Primary care

Mesh:

Substances:

Year:  2022        PMID: 35348948     DOI: 10.1007/s10787-022-00963-7

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN: 0925-4692            Impact factor:   4.473


  7 in total

1.  Loss of GABA-immunoreactivity in the spinal dorsal horn of rats with peripheral nerve injury and promotion of recovery by adrenal medullary grafts.

Authors:  T Ibuki; A T Hama; X T Wang; G D Pappas; J Sagen
Journal:  Neuroscience       Date:  1997-02       Impact factor: 3.590

2.  Peripheral nerve injury triggers central sprouting of myelinated afferents.

Authors:  C J Woolf; P Shortland; R E Coggeshall
Journal:  Nature       Date:  1992-01-02       Impact factor: 49.962

3.  Transsynaptic degeneration in the superficial dorsal horn after sciatic nerve injury: effects of a chronic constriction injury, transection, and strychnine.

Authors:  Tomosada Sugimoto; Gary J Bennett; Keith C Kajander
Journal:  Pain       Date:  1990-08       Impact factor: 6.961

Review 4.  Management strategies for herpes zoster and postherpetic neuralgia.

Authors:  Katherine E Galluzzi
Journal:  J Am Osteopath Assoc       Date:  2007-03

5.  A study of shingles and the development of postherpetic neuralgia in East London.

Authors:  Fiona T Scott; Mary E Leedham-Green; Winsome Y Barrett-Muir; Khidir Hawrami; W Jane Gallagher; Robert Johnson; Judith Breuer
Journal:  J Med Virol       Date:  2003       Impact factor: 2.327

6.  Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up.

Authors:  S Helgason; G Petursson; S Gudmundsson; J A Sigurdsson
Journal:  BMJ       Date:  2000-09-30

Review 7.  A review of the epidemiology of painful diabetic peripheral neuropathy, postherpetic neuralgia, and less commonly studied neuropathic pain conditions.

Authors:  Alesia Sadosky; Anne M McDermott; Nancy A Brandenburg; Marcie Strauss
Journal:  Pain Pract       Date:  2008 Jan-Feb       Impact factor: 3.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.